Incyte Corp
NASDAQ:INCY
Incyte Corp
Total Current Assets
Incyte Corp
Total Current Assets Peer Comparison
Competitive Total Current Assets Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Incyte Corp
NASDAQ:INCY
|
Total Current Assets
$4.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
24%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$38.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
22%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$14B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
1%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$28B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$13.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
25%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
See Also
What is Incyte Corp's Total Current Assets?
Total Current Assets
4.8B
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Total Current Assets amounts to 4.8B USD.
What is Incyte Corp's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
24%
Over the last year, the Total Current Assets growth was 22%. The average annual Total Current Assets growth rates for Incyte Corp have been 26% over the past three years , 21% over the past five years , and 24% over the past ten years .